Chemomab Therapeutics Ltd.
CMMBHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Chemomab Therapeutics Ltd. focuses on Biotechnology services and products. Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. The $10.8M market capitalization puts CMMB squarely in micro-cap range for its industry. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.
Market Cap
$10.8M
Beta
0.64
P/E (TTM)
—
P/E (Fwd)
-49.00
EPS (TTM)
$-1.12
EPS (Fwd)
$-0.03
ROE
-70.6%
ROA
-40.3%
Cash
$8.0M
Total Debt
$0
Free CF
—
52W Change
-67.2%
Annual Financials
Cash vs Debt
Where CMMB stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, CMMB finished 13.07% below its 150-day moving average ($1.76) and 24.63% below its 200-day moving average ($2.03). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CMMB overbought or oversold?
At the July 15, 2026 close, CMMB's RSI(14) was 50.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Chemomab Therapeutics Ltd. reports $8.0M in cash and $0 in total debt. ROE of -70.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Chemomab Therapeutics Ltd. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Chemomab Therapeutics Ltd.'s trajectory.